Key result
CAC score statin guidance fails to meet noninferiority versus PCE for MACE.
Why the trial?
Pooled cohort equations misclassify cardiovascular risk in many primary-prevention patients, while coronary artery calcium directly measures disease. CorCal asked whether CAC-guided statin allocation targets treatment better than risk-equation-guided care.
Does statin-initiation guidance based on a coronary artery calcium CT score reduce MACE compared to pooled cohort equations in adults without known ASCVD, diabetes, or prior statin therapy?
Population
5,772 adults without ASCVD, diabetes or prior statin; mean age 64, 51% women
Comparison
CAC CT score-guided vs pooled cohort equation-guided statin initiation
Design
Randomized noninferiority trial in one US system (Intermountain Health)
Follow-up
4.2 years
Authors
No takes yet. Share an insight, caveat, or question.
Experts see CorCal as a technically negative trial for coronary calcium-guided statin decisions, but the identical event rates and low overall events leave the field debating whether the noninferiority miss is a true signal against calcium scoring or a power problem.
CorCal found the same event rate whether statins were guided by calcium scoring or the pooled cohort equations, yet it failed its own noninferiority bar because events were rarer than anticipated. Some cardiologists read this as evidence that calcium scoring cannot replace standard risk equations, while others argue the matching outcomes with far fewer statin prescriptions vindicate a more targeted approach. The open question is whether guidelines should treat this as a negative result for calcium-guided prevention or as an underpowered draw that keeps the debate alive.
Does failing noninferiority end the case for calcium-guided statins, or do identical outcomes with fewer prescriptions support it?
What they’re arguing about
supportiveneutralcautiouscritical
Counts are expert takes we classified by axis. Tap a row to see the takes behind its count.
Whether the low event rate means CorCal was simply underpowered to detect a true difference, and whether a longer follow-up or larger trial could still establish noninferiority. Experts have not addressed whether these results will influence upcoming guideline revisions on the role of coronary calcium in primary prevention statin decisions.
Now that the RCT CAC advocates called for has come back negative, a scientific approach requires re-evaluating the case for calcium-guided prescribing. Statins are a reasonably benign intervention, and most of the population is already undertreated for dyslipidemia.
The study confirms a large body of evidence that a deterministic approach using the calcium score outperforms a probabilistic approach on an individual patient level.
MACE was identical at 2.7% in both arms, yet the noninferiority criterion was not met. CAC guidance led to fewer statin recommendations, but no RCT has demonstrated that CAC-guided therapy improves clinical outcomes.
CAC statin guidance failed noninferiority for MACE versus PCE; leaves open whether CAC can safely reduce statin prescriptions in primary prevention.
| Outcome | CAC | PCE |
|---|---|---|
| MACE (all-cause death, MI, stroke, or revascularisation) | 2.7% | 2.7% |
| Primary composite · HR 0.99 (95% CI 0.71-1.38); noninferiority criterion not met (p=0.045) | ||
| Adherence among patients recommended a statin | 62% | 23% |
| Process outcome · PCE guidance produced statin recommendations more than three times as often, but adherence was higher with CAC | ||
Statistical certainty
Event rates were far lower than expected, reducing power, and the identical 2.7% rates with a wide CI (0.71–1.38) make the comparison inconclusive rather than negative; noninferiority was not demonstrated.
Representation
Conducted within a single US health system, which may limit generalisability.
Design limitations
No safety data are reported in the record.
Does statin-initiation guidance based on a coronary artery calcium CT score reduce MACE compared to pooled cohort equations in adults without known ASCVD, diabetes, or prior statin therapy?
Hazard Ratio: 0.99 (95% CI 0.71–1.38)
Absolute Event Rate: 2.7% vs 2.7%
p-value: p=0.045 for noninferiority
CAC-guided statin initiation failed to meet noninferiority criteria for MACE compared to PCE guidance due to low event rates, though it resulted in fewer statin recommendations and higher patient adherence.
Journal, society, and media accounts. Useful signal, not independent expert judgment.
Joseph Muhlestein (2026) conducted an RCT in Primary prevention of ASCVD (n=5,772). Coronary artery calcium CT score guidance vs. Pooled cohort equations guidance was evaluated on MACE (all-cause mortality, myocardial infarction, stroke, or arterial revascularisation) (HR 0.99, 95% CI 0.71-1.38, p=0.045 for noninferiority). Statin-initiation guidance using a CAC score did not meet noninferiority compared to pooled cohort equations for MACE (HR 0.99; 95% CI 0.71-1.38; p=0.045 for noninferiority).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: